Question explored with the scientific record
Conversation so far
- 1 bioidentical hormones pros and cons
- 2 Is there strong evidence that bioidentical hormones work better than standard HT?
- 3 Is there any safety data for estradiol
- 4 What endometrial cancer or bleeding risks come with bioidentical progesterone?
- 5 What are the known endometrial cancer rates with estradiol+progesterone?
- 6 Is incidence for all cancers higher with HRT?
- 7 What are the risks for not taking hrt
- 8 Which HRT type (estrogen-only vs estrogen+progestin) is safest?
Answered on this page ↓
Which HRT type (estrogen-only vs estrogen+progestin) is safest?
The short version: estrogen-only therapy is safer than combined estrogen-progestin for breast cancer, but neither is safe enough to take without a clear reason.
The evidence here is dominated by the Women's Health Initiative (WHI), the largest randomized trial ever run on this question, and it is unusually good evidence for a drug question. The WHI was a placebo-controlled trial with hard clinical endpoints, not a manufacturer-funded observational study using surrogates. That matters. The WHI estrogen-progestin arm was stopped early because the harms crossed the boundary: a 26% increase in breast cancer (HR 1.26), a 29% increase in coronary heart disease, a 41% increase in stroke, and a doubled risk of pulmonary embolism [10]. The estrogen-only arm, in women with prior hysterectomy, showed the opposite for breast cancer: a 23% reduction (HR 0.77) and lower breast cancer mortality [3, 7]. The 2019 Lancet meta-analysis of 58 studies confirmed the pattern: combined therapy raised breast cancer risk from the first year of use (RR 1.6 for 1–4 years) and climbed to RR 2.08 for 5–14 years, while estrogen-only did not raise risk [3].
The mechanism is not mysterious. Progestins drive proliferation in breast tissue. A mouse study found combined therapy produced an 8–9 fold increase in mammary proliferation versus untreated controls, far more than estrogen alone [5]. Combined therapy also slows the natural decline in mammographic density, a known breast cancer risk factor [8].
| Outcome | Estrogen-only (CEE) | Estrogen + progestin | Source |
|---|---|---|---|
| Breast cancer incidence | HR 0.77 (reduced) | HR 1.26 (increased) | [3, 7, 10] |
| Breast cancer mortality | HR 0.60 (reduced) | HR 1.35 (increased) | [6] |
| Coronary heart disease | Not increased in WHI | HR 1.29 (increased) | [10] |
| Stroke | Increased | HR 1.41 (increased) | [10] |
| Venous thromboembolism | Increased | HR 2.13 (increased) | [10] |
| Endometrial cancer | Increased (unopposed) | HR 0.83 (protected) | [1, 2, 10] |
The trade-off is real. Estrogen-only raises endometrial cancer risk in women with a uterus, which is why progestin is added. But the added progestin shifts the risk profile dramatically: it protects the endometrium while raising breast cancer, heart disease, and clot risks. The net effect for a woman with a uterus is a choice between two bad options, not one safe one. For a woman without a uterus, estrogen-only is clearly safer on the cancer side.
The WISDOM trial, stopped early after WHI results, found a 7-fold increase in venous thromboembolism with combined therapy (HR 7.36) and a significant increase in cardiovascular events [4]. The USPSTF review concluded that neither formulation has net benefit for primary prevention of chronic disease [9].
My call: estrogen-only therapy is safer than combined estrogen-progestin for breast cancer and heart disease, but neither is low-risk. Combined therapy should be avoided unless endometrial protection is needed and the breast cancer risk is judged acceptable. Confidence: high for the breast cancer comparison, moderate for the overall risk-benefit because individual risk varies by age, genetics, and time since menopause.
Sources used 10
-
Postmenopausal vaginal bleeding in women using hormone replacement therapy
Combined estrogen–progestin HRT in postmenopausal women presenting with vaginal bleeding is associated with a significantly lower risk of endometrial cancer than non-use, with a non-significant trend toward higher risk with longer duration.
DOI: 10.1258/mi.2011.011111 -
Hormone Replacement Therapy (HRT) and its correlation with endometrial cancer in climacteric women: A systematic review
Estrogen-only hormone replacement therapy increases endometrial cancer risk in climacteric women, while regimens including progestogens mitigate risk, underscoring the need for individualized, monitored TRH use.
DOI: 10.56294/piii2023153 -
Menopausal hormone therapy: oncological risks
This narrative review surveys oncological risks of menopausal hormone therapy (MHT), concluding that combined MHT increases breast cancer risk, estrogen monotherapy has mixed effects, and MHT may increase ovarian cancer risk but reduce colorectal cancer risk, while evidence in B…
DOI: 10.26442/20795696.2020.3.200154 -
Main morbidities recorded in the women's international study of long duration oestrogen after menopause (WISDOM): a randomised controlled trial of hormone replacement therapy in postmenopausal women
A multicentre, randomized, double-blind trial (WISDOM) evaluating long-term cardiovascular, fracture, cancer, and death outcomes of hormone replacement therapy started in older postmenopausal women, finding increased cardiovascular and venous thromboembolism risk with combined e…
DOI: 10.1136/bmj.39266.425069.AD -
Experimental Mouse Model of Hormonal Therapy Effects on the Postmenopausal Mammary Gland
This study uses a mouse postmenopausal model to compare estrogen-alone versus combined estrogen+progestin therapy, delivered systemically or locally, and examines how pregnancy history influences mammary gland proliferation and morphology, finding that combined therapy elicits t…
DOI: 10.3233/bd-2006-24106 -
HUBUNGAN ANTARA HORMONE REPLACEMENT THERAPY DENGAN RISIKO KANKER PAYUDARA PADA WANITA PASCAMENOPAUSE
Estrogen-alone hormone replacement therapy lowers breast cancer risk in postmenopausal women, especially after hysterectomy, while estrogen-plus-progestin therapy increases risk, with long-term use and individual factors like BMI and breast density shaping the magnitude of risk …
DOI: 10.30743/jkin.v14i2.1064 -
Menopausal hormone therapy and breast cancer mortality: clinical implications
Combination menopausal hormone therapy with estrogen plus progestin increases breast cancer incidence and mortality and impairs detection, while estrogen alone reduces breast cancer incidence and mortality in women with prior hysterectomy, informing nuanced clinical use.
DOI: 10.1177/2042098614568300 -
Postmenopausal Hormone Therapy and Changes in Mammographic Density
This study quantified how postmenopausal hormone therapy (HT) use affects changes in mammographic density over time, finding that HT—especially combined estrogen-progestin therapy—slows the natural decline in density compared with nonusers, with larger effects seen after longer …
DOI: 10.1200/JCO.2005.04.7332 -
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women
The study updates the US Preventive Services Task Force recommendation on hormone therapy for the primary prevention of chronic conditions in postmenopausal women, concluding that combined estrogen and progestin, as well as estrogen alone, have no net benefit for this purpose.
DOI: 10.1001/jama.2017.18261 -
Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial
The Women's Health Initiative trial found that combined estrogen plus progestin therapy in healthy postmenopausal women increased the risk of coronary heart disease and breast cancer, leading to the conclusion that the health risks outweighed the benefits over an average follow-…
DOI: 10.1001/jama.288.3.321